Last updated on March 2020

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

Clinical Study Identifier: NCT03656536

Find a site near you

Start Over

Helsinki University Hospital

Helsinki, Finland
6.93miles
  Connect »

Docrates Cancer Center

Helsinki, Finland
8.53miles
  Connect »